Sonntag, 7. März 2021
Navigation öffnen
Anzeige:
Xospata
 
JOURNAL ONKOLOGIE – STUDIE

Digoxin Induced Dissolution of CTC Clusters

Rekrutierend

NCT-Nummer:
NCT03928210

Studienbeginn:
Juli 2020

Letztes Update:
18.09.2020

Wirkstoff:
Digoxin

Indikation (Clinical Trials):
Breast Neoplasms, Neoplastic Cells, Circulating

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Frühphase (Phase 0)

Sponsor:
University Hospital, Basel, Switzerland

Collaborator:
-

Studienleiter

Christian Kurzeder, PD Dr. med
Principal Investigator
Breast Cancer Center, University Hospital Basel

Kontakt

Studienlocations (1 von 1)

Breast Cancer Center, University Hospital Basel
4031 Basel
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Christian Kurzeder, PD Dr. med
Phone: +41 61 265 2525
E-Mail: christian.kurzeder@usb.ch
» Ansprechpartner anzeigen

Studien-Informationen

Detailed Description:

Circulating tumor cells (CTCs) are considered to be precursors of metastasis in various cancer types and are found in the blood of cancer patients as single CTCs and CTC clusters, with the latter featuring a higher ability to seed metastasis.

CTC cluster share several properties that commonly feature stem cell biology which drive metastases formation. Preclinical data shows that CTC clusters can be disaggregated into single cells by the treatment with cardiac glycosides such as digoxin. This single arm therapeutic exploratory study of digoxin in patients with advanced or metastatic breast cancer investigates whether cardiac glycosides are able to disrupt CTC clusters in breast cancer patients.

Patients with advanced or metastatic breast cancer in whom CTC clusters could be identified will receive an individualized daily maintenance dose of digoxin adapted to their kidney function. Blood samples for analyses of digoxin serum level and mean CTC cluster size will be drawn at specified time points.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Informed Consent as documented by signature

- Diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection, radiation therapy or systemic therapy with curative intent

- Adequate organ and marrow function

Exclusion Criteria:

- Patients on treatment with digoxin or digitoxin

- Patients with atrial fibrillation or atrial flutter

- Ventricular Fibrillation or ventricular tachycardia,

- Atrioventricular heart block 2nd or 3rd degree, sick sinus syndrome or sinus bradycardia,

- Wolff-Parkinson-White Syndrome

- Hypokalemia, hypercalcemia, hypomagnesemia, hypoxia,

- Hypertrophic cardiomyopathy, aortic aneurysm

- Simultaneous intravenous application of calcium salts

- Known hypersensitivity to Digoxin, other cardiac glycosides or included compounds

- Known drug interactions of ongoing cancer therapy with digoxin

- Women who are pregnant or breast feeding,

- Intention to become pregnant during the course of the study,

- Lack of safe contraception

- Other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease)

- Known or suspected non-compliance, drug or alcohol abuse

- Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant

- Participation in another study with investigational drug within the 30 days preceding and during the present study,

- Previous enrolment into the current study,

- Enrolment of the investigator, his/her family members, employees and other dependent persons

Studien-Rationale

Primary outcome:

1. Change in mean CTC cluster size (in ng/ml) (Time Frame - Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 10, on day 14, on day 17 and on day 21 after first oral intake of digoxin):
mean CTC cluster size (in patients with a digoxin serum level above 0.7 ng/ml) after treatment will be compared to mean CTC-cluster size before treatment



Secondary outcome:

1. Change in mean CTC cluster number (Time Frame - Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 10, on day 14, on day 17 and on day 21 after first oral intake of digoxin):
number of CTC-clusters before and after treatment will be compared

2. Average time to dissolution of CTC Clusters (in days) (Time Frame - Blood samples drawn at Screening, on day 0 (2 hours after first oral intake of digoxin), on day 3, on day 7, on day 10, on day 14, on day 17 and on day 21 after first oral intake of digoxin):
average time to dissolution of CTC clusters

Geprüfte Regime

  • Digoxin:
    Patients will receive a daily maintenance dose of digoxin. The daily dose of digoxin will be calculated according to the renal function and the target serum digoxin concentration and applied in an adjusted regimen based on the availability of 0.125 mg and 0.25 mg pills in the morning (before 10 am). Blood samples for analyses of mean CTC cluster size will be drawn at screening, on day 0 (2 hrs after first oral intake), on day 3 and on day 7. Depending on the digoxin serum level maintenance therapy with digoxin will be continued up to 3 weeks if the digoxin serum level on day 7 or day 14 is below 0.70 ng/ml. For the third week of maintenance therapy individual dose adjustments will be carried out as needed.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren

Darmkrebspatienten benötigen spezialisierte Anlaufstelle und Interessenvertretung

Darmkrebspatienten benötigen spezialisierte Anlaufstelle und Interessenvertretung
© Fotolia / cryonoid_media

Mit einem Pressegespräch am 19. April in Berlin nimmt EuropaColon Deutschland e. V. seine Tätigkeit als spezialisierte Anlaufstelle und Interessenvertretung von Darmkrebspatienten auf. Der neu gegründete Verein ist die deutsche Tochter der seit zwölf Jahren europaweit aktiven Patientenorganisation EuropaColon, die in 24 Ländern Europas Menschen mit Darmkrebs unterstützt und gegenüber der Gesundheitspolitik für deren Interessen eintritt. Der Verein soll Anlaufstelle...

Vorsorgevollmacht: Auch für Jüngere relevant

Vorsorgevollmacht: Auch für Jüngere relevant
©deagreez - stock.adobe.com

„Im Moment mache ich mir große Sorgen. Aus den Medien habe ich erfahren, dass ein schwerer Verlauf der Covid-19-Erkrankung auch jüngere Menschen ohne Vorerkrankungen treffen kann. Schutzmaßnahmen wie regelmäßiges Händewaschenund Abstandhalten setze ich alle um. Aber wie regele ich meine Angelegenheiten, falls ich doch erkranke und das so schwer, dass ich meinen Willen nicht mehr äußern kann?“ Martin S., Hannover

Seltene Krebsarten – Stiefkind der Krebsforschung?

Seltene Krebsarten – Stiefkind der Krebsforschung?
© Darren Baker / Fotolia.com

Eine seltene Krebsart bringt nicht nur Patienten, sondern auch Ärzte an ihre Grenzen. Dabei sind seltene Krebsarten gar nicht so selten wie die Bezeichnung vermuten lässt. Rund 100.000 Menschen erkranken in Deutschland jedes Jahr an einer solchen Krebserkrankung. Im aktuellen Monatsthema stellt das ONKO-Internetportal die wichtigsten seltenen Krebsarten, die damit verbundenen Herausforderungen bei der Therapie sowie Initiativen für betroffene Patienten vor.